NCT06795620View on ClinicalTrials.gov

Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Critical Limb Ischemia
Interventions
DRUG

Adipose tissue derived mesenchymal Stroma/stem Cells transplantation

Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.

Trial Locations (1)

Unknown

CHU Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER